Rebecca Araujo

Urban Health Today

In overweight or obese adults with cardiovascular disease, semaglutide significantly reduces the incidence of major adverse cardiovascular events (MACE) and was well-tolerated, according to results from <a href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=166301" target="_blank" rel="noopener">the SELECT trial</a>.Semaglutide, a drug developed by Novo Nordisk, is a GLP-1 receptor agonist that is indicated for chronic weight management alongside a reduced-calorie diet and increased physical activity. It is recommended for adults with a body mass index (BMI) of &ge;30 kg/m2 (obese), adults with a BMI of &ge;27 kg/m2 (overweight) and at least one weight-related comorbidity, or pediatric patients aged 12 years and older with a BMI at or over the 95th percentile for age and gender.The SELECT trial was a randomized, double-blinded, placebo-controlled trial that evaluated the efficacy of once-weekly semaglutide (2.4 mg) as an adjunct to the standard of care for preventing MACE in overweight or obese adults with no prior history of diabetes. The trial enrolled 17,604 adults aged &ge;45 years in 41 countries across 800 sites.The primary endpoint was the composite outcome of the first occurrence of MACE, defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal <a href="https://urbanhealthtoday.com/post/keto-diets-double-risk-heart-attack-stroke">stroke</a>. Secondary outcomes included mortality, cardiovascular risk factors, glucose metabolism, body weight, and renal function.Compared to those treated with the placebo, patients who received once-weekly semaglutide demonstrated a 20% reduction in MACE over a follow-up period of up to 5 years. The treatment appeared to have a safe and well-tolerated profile, in line with other trials of the drug at this dose.&ldquo;People living with obesity have an increased risk of cardiovascular disease but to date, there are no approved weight management medications proven to deliver effective weight management while also reducing the risk of heart attack, stroke or cardiovascular death. Therefore, we are very excited about the results from SELECT showing that semaglutide 2.4 mg reduces the risk of cardiovascular events,&rdquo; said Martin Holst Lange, executive vice president for Development at Novo Nordisk, in a press release. &ldquo;SELECT is a landmark trial and has demonstrated that semaglutide 2.4 mg has the potential to change how obesity is regarded and treated.&rdquo;Due to these results, Novo Nordisk is expected to file for regulatory approvals of a label indication expansion for semaglutide in the US and EU.

Lou Portero

Hidden Dangers: The Blood Sugar Crisis in Modern Breast Cancer Treatment

Diabetes in Women

New ACG Guidelines Address Critical Gastric Cancer Disparities in Non-White Americans

Gastroenterology

Ultra-Processed Foods Linked to Increased Ovarian and Breast Cancer Risk

Gynecologic Cancer

Latest News

Semaglutide Reduces Major Cardiovascular Events in Overweight and Obese Adults

Heart Disease Prevention

Semaglutide significantly reduced the risk of cardiovascular mortality, myocardial infarction, and stroke.

About Us

Editorial Policy

Contributors & Partners

Contact Us

eNewsletters

Work With Us

Advertising

Career Center

GU Oncology Now

Blood Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Food Allergy Roundtable Discussions

Allergy

Blood Cancers

— Multiple Myeloma

Breast Cancer

Colorectal Cancer

Pancreatic Cancer

Prostate Cancer

Cancer

Diabetes

Heart Failure

Heart Health

— Alzheimer’s Disease

Neurology

Public Health

Autoimmune Disease

Infectious Diseases

Obesity

Pediatrics

Sickle Cell Disease

Digital Health

Dermatology

Pulmonology

Video Insights

Workforce News

More

Heart Disease in Women

Menopause

Reproductive Health

Women’s Neurology

Well Woman Today

Roundtables

Podcasts

Conferences

Viewpoints

Subscribe